Harold W Peters

US Patent:

6899692, May 31, 2005

Filed:

Oct 17, 2001

Appl. No.:

09/981783

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Harold W. Peters - Martinez CA, US

Assignee:

Transvivo, Inc. - Napa CA

International Classification:

A61M001/34

US Classification:

604 609, 604 604, 604 504

Abstract:

A filter device for being implanted in a blood vessel for carrying out in-vivo plasma separation comprises one or more elongated hollow tubes and a plurality of elongated hollow microporous fibers, each fiber having a first and second end secured to one or more of the elongated hollow tubes with the interior lumen of each of the fibers communicating with the interior of the one or more of the hollow tubes, and wherein the fiber wall has a higher mass density zone adjacent to the outer wall surface and a lower mass density zone adjacent to the inner wall surface.

US Patent:

7195711, Mar 27, 2007

Filed:

Oct 6, 2004

Appl. No.:

10/959918

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Henry Grage - Alpharetta GA, US
Harold Handley, Jr. - Encinitas CA, US
Harold Peters - Martinez CA, US
Jacob C. Kearns - Martinez CA, US

Assignee:

Transvivo Inc. - Napa CA

International Classification:

B01D 69/08
B01D 71/68
B01D 63/02

US Classification:

21050023, 21050041, 604 604, 604 609, 604 27

Abstract:

An in-vivo plasmapheresis and/or in-vivo ultrafiltration membrane comprises elongated hollow fibers each fiber having an interior lumen extending along the fiber length, the fiber wall having a plurality of zones between the inner and outer wall surfaces, each of the zones having a mass density different than the mass density of an adjacent zone. The fiber wall is characterized by having a lower mass density zone at the inner wall surface and a higher mass density zone at the outer wall surface. The fiber is further characterized by having an average elongation breaking force strength of at least about 0. 2 lbs. and an average elongation of at least about 45%.

US Patent:

7354392, Apr 8, 2008

Filed:

Feb 25, 2004

Appl. No.:

10/786339

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Harold W. Peters - Martinez CA, US

Assignee:

Transvivo Inc. - Richmond CA

International Classification:

A61M 25/14

US Classification:

600 604, 604 609, 21032188

Abstract:

An elongated hollow microporous fiber comprises an inner wall surface defining an interior fiber lumen, an outer wall surface, and a microporous fiber wall therebetween, the fiber wall having one or more continuous, cohesive, elongated filaments embedded in the fiber and extending lengthwise of the elongated fiber along substantially the full length of the fiber.

US Patent:

7476210, Jan 13, 2009

Filed:

Dec 29, 2005

Appl. No.:

11/320866

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Tommy Gene Cooper - Friendswood TX, US
Harold W. Peters - Martinez CA, US

Assignee:

Transvivo Inc. - Napa CA

International Classification:

A61M 37/00

US Classification:

604 604, 604 609, 604 611, 604 401, 604 504, 604 601

Abstract:

Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

US Patent:

7481936, Jan 27, 2009

Filed:

Mar 11, 2005

Appl. No.:

11/078016

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Harold H. Handley - Encinitas CA, US
Harold W. Peters - Martinez CA, US

Assignee:

Transvivo Inc. - Yountville CA

International Classification:

B01D 61/14
B01D 61/18
B01D 63/02
B01D 63/04
B01D 61/00
B01D 63/00

US Classification:

210645, 210646, 210650, 210651, 21032169, 21032171, 21032188, 21032179, 21050023, 604 501, 604 601, 604 609

Abstract:

Patient fluid management is carried out by separating plasma from whole blood in vivo via an implantable filter device comprising one or more elongated hollow tubes and a plurality of elongated microporous fibers having an interior lumen extending along the length thereof, each fiber having a first and second end secured to the one or more elongated hollow tubes by passing plasma through the fiber wall from the outer wall surface to the inner wall surface and to the interior fiber lumen, directing the separated plasma to an ultrafiltration apparatus having a sieving coefficient cutoff between about 1×10and about 6×10daltons, separating plasma water and selected plasma components, from the separated plasma, and directing the treated plasma to the patient.

US Patent:

7572374, Aug 11, 2009

Filed:

Jan 18, 2006

Appl. No.:

11/334994

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Harold W. Peters - Martinez CA, US
Jacob C. Kearns - Martinez CA, US

Assignee:

Transvivo, Inc. - Napa CA

International Classification:

B01D 63/02
B01D 69/08
B01D 71/68

US Classification:

21050023, 210483, 210490, 210491, 21050041, 422 44, 604 604, 604 609

Abstract:

An in-vivo plasmapheresis or in-vivo ultrafiltration membrane comprises a plurality of elongated hollow microporous fibers each fiber having an outer wall, an inner wall and an interior lumen extending along the length thereof and defined by an inner wall surface, and wherein the fiber wall structure is a substantially continuous change in mass density from the outer wall to the inner wall and comprises a continuum of voids bounded by solid frames, the fiber wall having an asymmetrical pore size and asymmetrical mass density between said inner wall surface and the outer wall surface with a higher mass density adjacent to the outer wall and a lower mass density adjacent to said inner wall, and characterized by a nitric oxide donor composition capable of producing or releasing nitric oxide or inducing nitric oxide production or release in-vivo with a blood vessel, distributed on or in the fiber wall.

US Patent:

7585412, Sep 8, 2009

Filed:

Apr 14, 2006

Appl. No.:

11/404415

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Henry Grage - Alpharetta GA, US
Harold W. Peters - Martinez CA, US
Jacob C. Kearns - Martinez CA, US

Assignee:

Transvivo, Inc. - Napa CA

International Classification:

B01D 69/06
B01D 71/66
B01D 63/02

US Classification:

21050023, 21050041, 604 604, 604 609, 604 27

Abstract:

A plasmapheresis and/or ultrafiltration membrane comprises elongated hollow fibers each fiber having an interior lumen extending along the fiber length, the fiber wall having a plurality of zones between the inner and outer wall surfaces, each of the zones having a mass density different than the mass density of an adjacent zone. The fiber wall is characterized by having a lower mass density zone at the inner wall surface and a higher mass density zone at the outer wall surface. The fiber is further characterized by having an average elongation breaking force strength of at least about 0. 2 lbs. and an average elongation of at least about 45%.

US Patent:

8070706, Dec 6, 2011

Filed:

Jan 13, 2009

Appl. No.:

12/353209

Inventors:

Reynolds G. Gorsuch - Yountville CA, US
Tommy Gene Cooper - Friendswood TX, US
Harold W. Peters - Martinez CA, US

Assignee:

Transvivo, Inc. - Napa CA

International Classification:

A61M 37/00

US Classification:

604 604, 604 609, 604 611, 604 401, 604 501, 604 601

Abstract:

Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.